GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress
Clinical Science · 13.11.2026
DOI: 10.1042/cs20250134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, online erschienen am 13.11.2026. Verfasst von Luojing Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester Medical Center, Rochester, New York, United States. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases, HHS | NIH | National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Cisplatin, a potent chemotherapeutic agent, is highly effective in various cancers but its use is significantly limited by kidney injury, occurring in approximately 30% of patients. Cisplatin-induced kidney injury compromises optimal dosing, reducing cancer survival, and leads to permanent eGFR decline, increasing chronic kidney disease (CKD) risk and cardiovascular mortality. Increased reactive oxygen species (ROS) generation is central to cisplatin nephrotoxicity. Glutathione-S-transferase Mu-1 (GSTM1), a phase II detoxification enzyme, protects against oxidative stress. A common GSTM1 null deletion variant is highly prevalent in human populations. We hypothesized that GSTM1 deficiency increases susceptibility to cisplatin nephrotoxicity. Using a clinically relevant low-dose, repeat-cycle cisplatin mouse model, we found that cisplatin treatment significantly induces renal Gstm1 expression in wild-type mice, suggesting a protective role. Gstm1 knockout mice exhibited more severe kidney injury, evidenced by elevated creatinine, BUN, KIM-1, 4-HNE adducts, and histological damage. This exacerbated injury was associated with significantly higher renal ROS and NOX2 expression and mitochondrial ROS. In vitro studies using primary mouse proximal tubular cells deficient in Gstm1 and human HK-2 cells endogenously lacking GSTM1 demonstrated that GSTM1 deficiency leads to increased mitochondrial ROS and NOX2 expression following cisplatin treatment; conversely, overexpression of GSTM1 in HK-2 cells significantly attenuated cisplatin-induced mitochondrial ROS and NOX2 expression. Furthermore, GSTM1 protected against NF-κB activation and cell death. Our findings establish GSTM1 as a critical cytoprotective factor against cisplatin nephrotoxicity, mitigating oxidative stress, inflammation, and apoptosis, and identify the highly prevalent GSTM1 null variant as a potential genetic risk factor for cisplatin-induced kidney injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Rochester Medical Center, Rochester, New York, United States.
- University of California Irvine, Orange, California, United States.
- University of Miami School of Medicine, Miami, Florida, United States.
Förderung
- HHS | NIH | NIDDK | Division of Diabetes, Endocrinology, and Metabolic Diseases
- HHS | NIH | National Center for Advancing Translational Sciences
Zitieren
APA
Chen, L., Ayon, R. J., Mekhaiel, K. E., Beane, T., Zhao, Y., Mone, Y., Wang, Y. T., Alnuaimi, A., Ruiz, P., & Le, T. H. (2026). GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress. Clinical Science. https://doi.org/10.1042/cs20250134
Vancouver
Chen L, Ayon RJ, Mekhaiel KE, Beane T, Zhao Y, Mone Y, et al. GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress. Clinical Science. 2026. doi:10.1042/cs20250134
BibTeX
@article{Chen2026,
author = {Chen, Luojing and Ayon, Ramon J and Mekhaiel, Karen E and Beane, Timothy and Zhao, Yitong and Mone, Yuzana and Wang, Yves T and Alnuaimi, Ahmed and Ruiz, Phillip and Le, Thu H},
title = {GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress},
journal = {Clinical Science},
year = {2026},
doi = {10.1042/cs20250134}
}
EUVIMED